This mechanism is most likely responsible for the mucolytic effects of the drug, but may also explain the reported activity in Gaucher and Parkinson's disease.
The underlying process is likely to be the key factor behind the drug's mucolytic properties, potentially also playing a role in its effectiveness in treating Gaucher and Parkinson's disease.